Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.
作者信息
Urban C, Mariano N, Rahal J J, Tay E, Ponio C, Koprivnjak T, Weiss J
机构信息
Infectious Diseases Section The New York Hospital Medical Center of Queens Flushing, New York.
出版信息
Antimicrob Agents Chemother. 2001 Mar;45(3):994-5. doi: 10.1128/AAC.45.3.994-995.2001.
Abstract
摘要
相似文献
1
Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.对重组杀菌/通透性增加蛋白（BPI）和天蚕素P1敏感的耐多粘菌素B鲍曼不动杆菌临床分离株
Antimicrob Agents Chemother. 2001 Mar;45(3):994-5. doi: 10.1128/AAC.45.3.994-995.2001.
2
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.耐多粘菌素、耐碳青霉烯类鲍曼不动杆菌可被三种单独无活性的药物联合使用所根除。
J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.
3
Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.天蚕素A-蜂毒素杂合肽对鲍曼不动杆菌耐黏菌素临床分离株的抗菌活性研究
J Antimicrob Chemother. 2006 Jul;58(1):95-100. doi: 10.1093/jac/dkl145. Epub 2006 Apr 24.
4
Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.黏菌素与多黏菌素 B 对泛耐药和广泛耐药鲍曼不动杆菌的协同作用。
Int J Antimicrob Agents. 2019 May;53(5):663-668. doi: 10.1016/j.ijantimicag.2019.03.009. Epub 2019 Mar 14.
5
In vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii.多粘菌素B对耐碳青霉烯鲍曼不动杆菌的体外活性
J Med Assoc Thai. 2014 Dec;97(12):1254-8.
6
Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.天蚕素A-蜂毒素杂合肽对鲍曼不动杆菌耐黏菌素临床菌株的活性：作用差异机制的分子基础
Antimicrob Agents Chemother. 2006 Apr;50(4):1251-6. doi: 10.1128/AAC.50.4.1251-1256.2006.
7
Polymyxin Resistance Among XDR ST1 Carbapenem-Resistant Clone Expanding in a Teaching Hospital.在一家教学医院中不断扩大的耐碳青霉烯类XDR ST1克隆中多粘菌素耐药情况
Front Microbiol. 2021 Mar 26;12:622704. doi: 10.3389/fmicb.2021.622704. eCollection 2021.
8
Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.抗蠕虫药氯氰碘柳胺增强多粘菌素B对多重耐药鲍曼不动杆菌的杀菌作用。
J Antibiot (Tokyo). 2016 Jun;69(6):415-21. doi: 10.1038/ja.2015.127. Epub 2015 Dec 16.
9
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Using Checkerboard Information.舒巴坦/美罗培南/多黏菌素 B 联合用药对极度耐药的药效学影响。采用棋盘信息法。
Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.
10
Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR : a retrospective cohort study.静脉联合鞘内/脑室注射多黏菌素 B 治疗神经外科术后耐多药/广泛耐药颅内感染的疗效：一项回顾性队列研究。
Antimicrob Resist Infect Control. 2018 Jan 19;7:8. doi: 10.1186/s13756-018-0305-5. eCollection 2018.
引用本文的文献
1
Molecular typing, and integron and associated gene cassette analyses in strains isolated from clinical samples.对从临床样本中分离出的菌株进行分子分型、整合子及相关基因盒分析。
Exp Ther Med. 2020 Sep;20(3):1943-1952. doi: 10.3892/etm.2020.8911. Epub 2020 Jun 19.
2
Integrative analysis of outer membrane vesicles proteomics and whole-cell transcriptome analysis of eravacycline induced Acinetobacter baumannii strains.外膜囊泡蛋白质组学和依拉环素诱导鲍曼不动杆菌全细胞转录组分析的综合分析。
BMC Microbiol. 2020 Feb 11;20(1):31. doi: 10.1186/s12866-020-1722-1.
3
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.致病不动杆菌属物种的抗生素耐药性和新兴的联合治疗。
J Microbiol. 2017 Nov;55(11):837-849. doi: 10.1007/s12275-017-7288-4. Epub 2017 Oct 27.
4
Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center.比利时一家烧伤伤口中心中醋酸钙不动杆菌-鲍曼不动杆菌复合体的分子流行病学及临床影响
PLoS One. 2016 May 25;11(5):e0156237. doi: 10.1371/journal.pone.0156237. eCollection 2016.
5
High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.高效液相色谱-质谱法测定人血浆中多黏菌素 B1 和 B2 的含量。
Ther Drug Monit. 2012 Aug;34(4):398-405. doi: 10.1097/FTD.0b013e31825c827a.
6
The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.pmrCAB 操纵子通过脂质 A 上的磷乙醇胺修饰介导鲍曼不动杆菌 ATCC 17978 和临床分离株对多黏菌素的耐药性。
Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51. doi: 10.1128/AAC.00256-11. Epub 2011 Jun 6.
7
Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.Etest、微量稀释棋盘法和时间杀菌法检测泛耐药鲍曼不动杆菌的协同作用。
Antimicrob Agents Chemother. 2010 Nov;54(11):4678-83. doi: 10.1128/AAC.00497-10. Epub 2010 Aug 16.
8
Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.替加环素与亚胺培南治疗实验性鲍曼不动杆菌肺炎小鼠的疗效比较。
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):527-31. doi: 10.1007/s10096-010-0890-6. Epub 2010 Feb 25.
9
Acinetobacter baumannii: emergence of a successful pathogen.鲍曼不动杆菌：一种成功病原体的出现
Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07.
10
Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.加利福尼亚州洛杉矶县医院感染暴发中鲍曼不动杆菌临床分离株的表型和分子特征
J Clin Microbiol. 2008 Aug;46(8):2499-507. doi: 10.1128/JCM.00367-08. Epub 2008 Jun 4.
本文引用的文献
1
Acinetobacter.
Semin Respir Crit Care Med. 2000;21(4):341-8. doi: 10.1055/s-2000-9858.
2
Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.采用脑室注射硫酸多粘菌素B钠成功治疗耐碳青霉烯鲍曼不动杆菌引起的脑室炎。
Clin Infect Dis. 1999 Apr;28(4):916-7. doi: 10.1086/517243.
3
In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.非传统抗菌药物对重症监护病房暴发中分离出的多重耐药鲍曼不动杆菌菌株的体外活性。
Antimicrob Agents Chemother. 2000 Apr;44(4):1035-40. doi: 10.1128/AAC.44.4.1035-1040.2000.
4
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.静脉注射黏菌素治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌引起的医院感染。
Clin Infect Dis. 1999 May;28(5):1008-11. doi: 10.1086/514732.
5
Peptide antibiotics.肽类抗生素
Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23. doi: 10.1128/AAC.43.6.1317.
6
Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group.创伤性出血患者使用杀菌/通透性增加蛋白（rBPI21）：一项多中心II期临床试验的结果。rBPI21急性出血性创伤研究组
J Trauma. 1999 Apr;46(4):667-76; discussion 676-7. doi: 10.1097/00005373-199904000-00018.
7
Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis.重组人杀菌/通透性增加蛋白氨基末端片段在儿童严重脑膜炎球菌败血症中的初步评估
Lancet. 1997 Nov 15;350(9089):1439-43. doi: 10.1016/s0140-6736(97)06468-4.
8
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.不动杆菌属作为医院感染病原菌：微生物学、临床及流行病学特征
Clin Microbiol Rev. 1996 Apr;9(2):148-65. doi: 10.1128/CMR.9.2.148.
9
Antiendotoxin activity of cationic peptide antimicrobial agents.阳离子肽抗菌剂的抗内毒素活性。
Infect Immun. 1996 Dec;64(12):4922-7. doi: 10.1128/iai.64.12.4922-4927.1996.
10
Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine.猪肠道来源的两种抗菌肽——天蚕素P1和PR-39对大肠杆菌的作用机制
Infect Immun. 1993 Jul;61(7):2978-84. doi: 10.1128/iai.61.7.2978-2984.1993.
Zotero 插件